NBY vs PCYO

For growth investors, NovaBay Pharmaceuticals, Inc.

(NBY) is the stronger pick with -6. 4% revenue growth year-over-year, versus -9. 3% for Pure Cycle Corporation (PCYO). Pure Cycle Corporation (PCYO) offers the better valuation at 21. 6x trailing P/E, making it the more compelling value choice. Analysts rate Pure Cycle Corporation (PCYO) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pure Cycle Corporation (PCYO) delivered a total return of -19.

8%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: PCYO returned +159. 6% versus NBY's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pure Cycle Corporation (PCYO) is the lower-risk stock at 0.

79β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately 206% more volatile than PCYO relative to the S&P 500.

By revenue growth (latest reported year), NovaBay Pharmaceuticals, Inc.

(NBY) is pulling ahead at -6. 4% versus -9. 3% for Pure Cycle Corporation (PCYO). On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc. grew EPS 98. 2% year-over-year, compared to 12. 5% for Pure Cycle Corporation. Over a 3-year CAGR, PCYO leads at 4. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pure Cycle Corporation (PCYO) is the more profitable company, earning 50.

3% net margin versus -73. 8% for NovaBay Pharmaceuticals, Inc. — meaning it keeps 50. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PCYO leads at 29. 4% versus -59. 7% for NBY. At the gross margin level — before operating expenses — NBY leads at 66. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Pure Cycle Corporation (PCYO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

79), +159. 6% 10Y return). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PCYO: +159. 6%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NBY (Healthcare) and PCYO (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.